TVTX

Company Overview — What Does Travere Therapeutics, Inc. Do?

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Travere Therapeutics, Inc. (TVTX) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Eric M. Dube and employs approximately 460 people, headquartered in SAN DIEGO, California. With a market capitalization of $2.9B, TVTX is one of the notable companies in the Healthcare sector.

Travere Therapeutics, Inc. (TVTX) Stock Rating — Hold (April 2026)

As of April 2026, Travere Therapeutics, Inc. receives a Hold rating with a composite score of 36.9/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.TVTX ranks #1,280 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Travere Therapeutics, Inc. ranks #98 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TVTX Stock Price and 52-Week Range

Travere Therapeutics, Inc. (TVTX) currently trades at $28.90. The stock lost $2.54 (8.1%) in the most recent trading session. The 52-week high for TVTX is $42.13, which means the stock is currently trading -31.4% from its annual peak. The 52-week low is $12.91, putting the stock 123.9% above its annual trough. Recent trading volume was 2.8M shares, reflecting moderate market activity.

Is TVTX Overvalued or Undervalued? — Valuation Analysis

Travere Therapeutics, Inc. (TVTX) carries a value factor score of 32/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 20.72x, compared to the Healthcare sector average of 23.63x — a discount of 12%. The price-to-book ratio stands at 25.48x, versus the sector average of 2.75x. The price-to-sales ratio is 6.90x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, TVTX trades at 12.93x EV/EBITDA, versus 6.34x for the sector.

At current multiples, Travere Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Travere Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Travere Therapeutics, Inc. (TVTX) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -72.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -13.7% versus the sector average of -33.1%.

On a margin basis, Travere Therapeutics, Inc. reports gross margins of 97.4%, compared to 71.5% for the sector. The operating margin is -34.4% (sector: -66.1%). Net profit margin stands at -33.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 204.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TVTX Debt, Balance Sheet, and Financial Health

Travere Therapeutics, Inc. has a debt-to-equity ratio of 427.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 2.74x, indicating strong short-term liquidity. Total debt on the balance sheet is $311M. Cash and equivalents stand at $111M.

TVTX has a beta of 1.19, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Travere Therapeutics, Inc. is 40/100, reflecting average volatility within the normal range for its sector.

Travere Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Travere Therapeutics, Inc. reported revenue of $424M and earnings per share (EPS) of $-0.29. Net income for the quarter was $-83M. Gross margin was 97.4%. Operating income came in at $-87M.

In FY 2025, Travere Therapeutics, Inc. reported revenue of $491M and earnings per share (EPS) of $-0.29. Net income for the quarter was $-26M. Gross margin was 97.9%. Revenue grew 110.5% year-over-year compared to FY 2024. Operating income came in at $-63M.

In Q3 2025, Travere Therapeutics, Inc. reported revenue of $165M and earnings per share (EPS) of $0.29. Net income for the quarter was $26M. Gross margin was 99.0%. Revenue grew 162.1% year-over-year compared to Q3 2024. Operating income came in at $25M.

In Q2 2025, Travere Therapeutics, Inc. reported revenue of $114M and earnings per share (EPS) of $-0.14. Net income for the quarter was $-13M. Gross margin was 98.7%. Revenue grew 111.5% year-over-year compared to Q2 2024. Operating income came in at $-13M.

Over the past 8 quarters, Travere Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $54M to $424M. Investors analyzing TVTX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TVTX Dividend Yield and Income Analysis

Travere Therapeutics, Inc. (TVTX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TVTX Momentum and Technical Analysis Profile

Travere Therapeutics, Inc. (TVTX) has a momentum factor score of 54/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 53/100 reflects moderate short selling activity.

TVTX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Travere Therapeutics, Inc. (TVTX) ranks #98 out of 838 stocks based on the Blank Capital composite score. This places TVTX in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TVTX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TVTX vs S&P 500 (SPY) comparison to assess how Travere Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

TVTX Next Earnings Date

No upcoming earnings date has been announced for Travere Therapeutics, Inc. (TVTX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TVTX? — Investment Thesis Summary

Travere Therapeutics, Inc. presents a balanced picture with arguments on both sides. The quality score of 24/100 flags below-average profitability. The value score of 32/100 indicates premium valuation.

In summary, Travere Therapeutics, Inc. (TVTX) earns a Hold rating with a composite score of 36.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TVTX stock.

Related Resources for TVTX Investors

Explore more research and tools: TVTX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TVTX head-to-head with peers: TVTX vs AZN, TVTX vs SLGL, TVTX vs VMD.